A: Principles of resource allocation in critical care
Authors
Dr Najwan Abu Al-Saad BSc MBBS MSc FRCA FFICM DFPH
ST7 Anaesthesia & Intensive Care
Department of Anaesthetics
Norfolk & Norwich University Hospital

Dr Chris Skedgel PhD
Senior Lecturer in Applied Health Economics
Norwich Medical School
University of East Anglia

Dr Jurgens Nortje MBChB FRCA FFICM MD (corresponding author)
Consultant Anaesthesia & Intensive Care Medicine
Department of Anaesthetics
Norfolk & Norwich University Hospital
Colney Lane
Norwich
Norfolk
NR4 7UY
Tel: 01603 287 074
Fax: 01603 287 886
Email: jurgens.nortje@nnuh.nhs.uk

Key words:
Intensive care, Management, Ethics
Total expenditure for adult critical care in England, Wales and
Northern Ireland in 2008/2009 amounted to £1 billion\(^1\),
approximately 1% of the total National Health Service (NHS)
Budget. Spending on health in the UK represents
approximately 9% of Gross Domestic Product (GDP), which is
comparable with other Organisation for Economic
Cooperation and Development (OECD) countries\(^2\). However,
there is a well-recognised, wide variation in spending on
critical care internationally not fully explained by differences in
epidemiology of critical illness or variations in the definition of
critical care, though the latter makes direct comparisons of the
funding and organisation of critical care between countries
problematic. Such variations are also independent of national
GDP and proportion of GDP allocated to health.

Although critical care is a high-cost, low-volume specialty\(^1\),
especially relative to preventative or primary care
interventions, there is evidence that critical care provision in
the UK NHS can be very cost-effective\(^3,4\).

Acting in individual patients’ best interests when presenting to
critical care is the central tenet of clinical practice. Yet
healthcare delivery in all settings occurs in the context of finite
resources and ever-increasing demand, making it a scarce
resource. Drivers for rising demand\(^5\) in critical care include:
• an ageing population living longer with multiple long-term conditions
• increasing number and complexity of surgical interventions performed
• development of new therapies
• rising public expectations of the availability and effectiveness of healthcare based in improved outcomes over time. An observational study in Australia and New Zealand\(^6\) showed in-hospital mortality secondary to severe sepsis and septic shock decreased year on year between 2000 and 2012 from 35% to 18.4%, unrelated to changes in case definitions or illness severity.

B: Scarcity and rationing
The relative scarcity of healthcare necessitates alignment of individual patient interests with sustainable models of providing healthcare. The NHS Commissioning Board\(^7\) (NHSCB) acknowledges that it ‘does not have the budget to fulfil all needs of all patients within its area of responsibility’. The US Task Force on Values, Ethics and Rationing in Critical Care\(^8\) defines rationing as ‘the allocation of healthcare resources in the face of limited availability, which necessarily means that beneficial interventions are withheld from some individuals’.

Rationing within healthcare occurs at three levels\(^9\):
• Macro-level rationing at state or national government level when determining overall health budgets, with governments being accountable to their electorates.

• Meso-level rationing regionally or locally e.g. Clinical Commissioning Groups (CCGs) that are accountable to the Secretary of State for Health via NHS England, assessed broadly by their population health outcomes and spending.

• Micro-level rationing, also referred to as bedside rationing, occurs at the level of individual clinicians and patients. The General Medical Council’s (GMC) leadership and management guidance\(^\text{10}\) states all doctors should be prepared to contribute to discussions about resource allocation, priority setting and commissioning of services for the wider patient population. Decisions affecting patients should be ‘fair, based on clinical need and the likely effectiveness of treatments’, acknowledging that ‘treatment options that can be offered to patients may be affected by limits in resources’.

B: Who should have access to critical care?
There are various approaches to determining who needs access to healthcare\(^\text{11}\). Clinical need is often defined in terms of capacity to benefit from available therapies. This is in
keeping with the GMC’s leadership guidance and the NHSCB definition of a healthcare need as a health problem that ‘can be addressed by a clinically effective intervention’. Conversely, denying patients access to interventions where there is little or no expected health benefit is not rationing.

In critical care, cost-effectiveness of admission is also related to capacity to benefit. The most critically-ill patients have the most to gain (in terms of mortality reduction) from admission. As many costs of ICU are fixed irrespective of illness severity, the cost-effectiveness of admitting patients with higher predicted mortality improves in comparison to those with lower predicted mortality. A multicentre prospective observational study (Table 1) showed that the effectiveness (relative risk reductions in 28-day mortality) for patients admitted to ICU compared with non-admitted referrals varied with predicted mortality. Similarly, the cost-effectiveness of ICU admission (cost per life saved and cost per life-year saved) was greatest for patients with predicted mortality ≥ 40%.

The strategic aims of NHS England regarding provision of critical care are to:
- Prevent *avoidable* mortality and morbidity due to patients requiring critical care not accessing the appropriate level of care or organ support.

- Avoid triage by resource as opposed to triage by outcome. Patients should have access to care based on anticipated capacity to benefit from treatment rather than on what facilities are available (namely availability of staffed ICU beds).

- Achieve equity of access to treatment. Patients with equivalent clinical need (in terms of severity of illness and capacity to benefit) should have equal access to optimal care irrespective of, for example, location or time of presentation.

**B: Value, cost-effectiveness and efficiency in critical care**

Value for money in healthcare can be defined as achieving best health outcomes relative to cost\(^4\). The objective of health economics is to maximise the value obtained from a given set of resources by prioritising interventions delivering greatest health benefits for cost. Cost- effectiveness is synonymous with value for money although it tends to imply value for money determined by means of a cost-effectiveness analysis (CEA).

Measurement of value for money in critical care includes the use of the Intensive Care National Audit and Research Centre
Case Mix Programme\textsuperscript{15} (ICNARC CMP) to aid ‘decision-making, resource allocation and local quality improvement.’

There are two types of efficiency in health economics\textsuperscript{9}. First, \textit{allocative efficiency} is concerned with ensuring that the value derived from a service outweighs the costs of its production. The greater the value relative to cost, the more allocatively efficient the service. The second type of efficiency is \textit{technical efficiency}, which is concerned with maximising the outcomes available with a given level of resources. The more outcomes that can be produced for a given budget, the more technically efficient the service.

Questions around what the best proportion of healthcare spending that should be allocated to critical care is (budget setting), and which groups of patients should have access to critical care (case selection) address allocative efficiency. Technical efficiency considers how a given budget can best be used to maximise delivery or minimise cost of a service.

Clinical governance and quality improvement projects in critical care largely focus on the technical efficiency of service provision through improving processes and cost-containment at a local or regional level. Critical care admission practices could affect both local allocative efficiency and technical
efficiency. It is possible for a service to be technically efficient while being allocatively inefficient.

B: Economic evaluation in critical care
Economic evaluations in critical care can provide evidence to improve efficiency of resource allocation\textsuperscript{16}. Comparisons between interventions within critical care can be made to prioritise how resources are best utilised within the specialty, as well as against very different uses of scarce healthcare resources. The main types of health economic evaluation\textsuperscript{9,16,17} are:

- **Cost-benefit analysis (CBA):** Total costs and total benefits of interventions (measured purely in monetary terms) are compared. This requires a monetary value to be assigned to all outcomes. For example, if comparing methods of weaning sedation and ventilatory support, a monetary cost would need to be assigned to outcomes such as an episode of delirium or pain and distress experienced by patients. CBA has the advantage of being able to assess allocative efficiency but the information requirements are onerous and monetising health outcomes can be viewed as morally objectionable.
• **Cost-minimisation analysis (CMA):** In circumstances where the effects of the interventions are therapeutically *identical*, the objective is to identify the lowest cost option. That is, outcomes including side-effect profiles and duration of treatment between compared interventions are equivalent. Such evaluations have been used to compare drug treatments but it is rare for therapies to have identical outcomes so their role is increasingly narrow.

• **Cost-effectiveness analysis (CEA):** An economic evaluation whose outcome measure is one of incremental cost-effectiveness i.e. the difference in cost between two interventions divided by the difference in their effect. This involves estimating or measuring the total costs of an intervention against the health benefits measured in natural units such as premature deaths avoided, cases prevented or changes in measures such as ICU or hospital length of stay. Table 1 shows some examples of CEA s within critical care. CEA is relatively straightforward but can only be used to compare interventions with the same outcome measures e.g. 28-day mortality. Cost effectiveness is expressed in terms of the additional cost per unit of effect, such as cost per life saved. This is also known as
the Incremental Cost Effectiveness Ratio (ICER). The
denominator, difference in effect between intervention
and control, is equivalent to the Absolute Risk
Reduction (ARR) between groups.

\[
\text{Incremental Cost Effectiveness Ratio} = \frac{\text{Costs of intervention} - \text{Costs of control}}{\text{Effect of intervention} - \text{Effect of control (ARR)}}
\]

- **Cost-utility analysis (CUA):** This is a special case of
cost-effectiveness analysis where the effects are
measured in terms of a utility (a measure of preference
or value that an individual or society assigns a health
state). The most widely used utility measure is the
Quality Adjusted Life Year (QALY). By standardising the
outcome measure, CUAs allow direct comparison of
very different health interventions with different
health benefits. This facilitates explicit resource
allocation decisions such as those made by the UK
National Institute for Health and Care Excellence
(NICE), where treatments under £20,000 per QALY
gained are generally considered cost-effective and
those above £30,000\(^3\) per QALY are less frequently
approved.
C: QALYs and measuring health utility

QALYs are a composite measure of the state of health of a person or group in which benefits, in terms of length of life, are adjusted to reflect the quality of life. Using QALYs as a composite outcome measure allows morbidity and mortality to be considered together\textsuperscript{18,19}. QALYs are calculated by weighting each expected year of life by the quality, or utility, of that year on a scale of 0 (dead) to 1 (perfect health). For example, 1 year of life in perfect health would count as 1.0 QALYs, whilst one year at 60% of full health would count as 0.6 QALYs. For health states seen as worse than death, a negative utility value can be assigned.

A US study of predictors of health utilities in Acute Respiratory Distress Syndrome (ARDS) survivors using the Euro Quality of Life 5 Dimension (EQ-5D) Health Related Quality of Life (HRQoL) questionnaire, reporting extreme problems in all five domains corresponded with a calculated health utility of -0.11 compared with utility of 1.0 with no problems in any of domains\textsuperscript{21}.

Health state utilities can be elicited directly, using techniques such as the standard gamble (SG) or time trade-off (TTO), or indirectly (Figure 1), using generic HRQoL questionnaires such as the Short Form (36) Health Survey (SF-36) or EQ 5D. With direct approaches individuals are asked to rate their health
across a series of dimensions. These ratings are assigned utility scores derived using TTO methods in a different sample of the general population. Indirect methods are more straightforward to administer and are much more common in health economic evaluations than direct methods, but it is important to recognise the potential for divergence between the preferences of the patients rating the health states and the public sample involved in eliciting the utility weights. Such differences have implications for the estimation of QALYs and cost-effectiveness of interventions.

In the same way that clinical evidence needs to be critically appraised to understand how transferable the evidence is to a local population or case-mix, health economic evaluations also need to be understood in a local context and are perhaps even more context-sensitive as costs vary greatly between health systems and over time.

One cost that should ideally be included in estimates of total costs of interventions or models of care is opportunity cost. When choices are made regarding how best to use scarce resources, there is always a next-best alternative that cannot be chosen. This is the opportunity cost: the value of the best, mutually exclusive alternative foregone to pursue a certain action. For example, in critical care, part of the total cost of
buying specific equipment or funding interventions is the value that could otherwise be gained by the next-best use of the same resources, either within critical care or a different treatment area. Similarly, the impact of micro-level resource allocation decisions that lead to an ICU operating at full capacity (even when such decision-making is optimal) occurs at the cost of being able to admit new referrals in a timely manner, with potentially harmful consequences21,22.

**C: Challenges in measuring cost-effectiveness**

Maximising the value\textsuperscript{14} of critical care by improving clinical outcomes is key to efficient resource allocation. If acting in patients’ best interests is at the heart of good practice, then the outcomes measured need to be of importance and relevance to patients. Outcomes measured in much critical care research have often focused on short-term mortality (at best), changes in physiological parameters or process measures (such as length of stay) used as proxies for improved clinical outcomes. As short-term mortality has improved, so research is increasingly aimed at longer-term mortality, morbidity, HRQoL\textsuperscript{23} and socio-economic impact of critical illness on patients\textsuperscript{24} and carers.

Apart from the practical difficulties in measuring longer-term patient-centred outcomes, critical care outcomes research faces many challenges. First, the heterogeneity of the patient
population within critical care, both in terms of the pre-existing health status of patients and the diversity of critical illness presentations such as sepsis, trauma and respiratory failure. Second, outcomes in critical care are heavily dependent on performance in many other clinical areas such as the Emergency Department, operating theatres, pre-hospital and diagnostic services. Therefore, measuring outcomes directly attributable solely to critical care is difficult. Third, outcomes research attempting to predict patient outcome, such as illness severity scoring systems, provide estimates of outcome probability at a population level which are not transferable to individual patients. Similarly, measuring costs of critical care are equally challenging. Current measures focus largely on generating an average daily cost for critical care multiplied by length of patient stay to give an estimate of cost for length of ICU stay. First, as with outcomes, costs of critical care are heavily dependent on areas outside the critical care unit. Second, cost of critical care is not constant throughout patient stay. Patient stay tends to be particularly resource intensive early in the ICU admission and less so as length of stay increases. Third, the heterogeneous case-mix means patient costs can be very variable. Fourth, despite difficulties in accurate measurement of short-term ICU costs, an idea of resource utilisation by
survivors of ICU in the community is needed to estimate the true cost-effectiveness of providing critical care.

C: Appraising CEAs in critical care

The reliability of any CEA is only as good as the quality of the data it is based on. For an intervention to be cost-effective, it must first be shown to be clinically effective. The more robust the clinical effectiveness data, the less uncertainty surrounds the cost-effectiveness estimates. Defining effective critical care interventions as those which lead to improved survival and health of those exposed to critical illness requires evidence of meaningful improvements in patient-centred outcomes, namely sustained reductions in mortality with satisfactory functional recovery and HRQoL. The short-term outcome measures most commonly used in ICU studies are not well suited to robust CEAs.

In addition, the costs and effects considered depend on the perspective chosen for the valuation and this needs to be stated in any health economic analysis. This could be at the level of an individual ICU, hospital, national health system or a societal perspective. The latter is preferred because it is the broadest perspective, considering all costs and benefits, including those incurred in sectors outside health and the impact of interventions on caregivers. NICE guidelines,
however, currently recommend a payer perspective as it is more relevant to funding decisions. In the NHS, this would be the commissioning board or the local CCG. With the drive toward integration of health and social care, a societal perspective may be increasingly needed to compare different interventions or models of care.

A systematic review of CEAs in critical care\textsuperscript{16} found that 2 of 14 studies assessed, used a societal perspective in evaluating cost-effectiveness. These were both assessing the economic impact of activated protein C in sepsis, a treatment where considerable prospective cost-effectiveness data was published. Though this evidence is now largely obsolete since the drug was withdrawn due to doubts around the evidence of its clinical effectiveness and safety, the methodology is still noteworthy.

Sensitivity analysis is a technique used in economic evaluations to vary the underlying assumptions of costs or effects used in the analysis and around which there is uncertainty. It allows multiple ‘what if?’ scenarios to be performed\textsuperscript{16}, testing the robustness of the conclusions and is recommended when conducting CEAs.

Discounting\textsuperscript{25} is performed to account for ‘time preference’. This is the idea that people weight costs and benefits that
occur now more strongly than costs and benefits that will occur in the future. For example, most individuals would prefer to receive £100 today to £100 a year from today. Similarly, a QALY gained in the present is valued more highly than one in the future. The discount rate represents the degree to which future events are less heavily weighted, or discounted. 3.5% is the discount rate recommended and used by NICE.

Analysing the cost-effectiveness of specific interventions within critical care from the perspective of the individual unit or hospital trust may sometimes be sufficient to guide resource allocation decisions. Minimising costs at the level of a hospital trust or individual unit is important, provided the effectiveness of care is not compromised. However, cost minimisation within critical care may simply serve to displace costs to a different part of the health service or the community. While this may benefit fiscal management within a hospital trust or directorate, it merely represents cost-shifting as there is no gain in overall efficiency or cost-effectiveness of the system.

**B: Conclusion**

The excess demand for healthcare relative to supply means not all beneficial health interventions can be funded. Rationing is, therefore, an unavoidable feature of health systems.
There is evidence that critical care can be a very cost-effective use of healthcare resources compared with other interventions. However, demand for critical care is continually rising. As short-term survival following intensive care continues to improve, measuring longer-term patient-centred outcomes is increasingly important to guide resource allocation decisions. Estimating both the direct and indirect costs of critical care provision to the health system, patients, carers and wider society need to be included in health economic evaluations of critical care. Although significant challenges exist in measurement of both outcomes and costs, doing so would produce increased understanding of how to sustainably deliver valuable critical care.
References


   last accessed 17th September 2016


7. Commissioning Policy: Ethical framework for priority setting and resource allocation. NHS Commissioning Board April 2013


10. Leadership and management for all doctors. General Medical Council, Manchester 2012


ncite respiratory distress syndrome. *Thorax*

*Online First:* published July 20th 2016 doi:

10.1136/thoraxjnl-2016-208560


10.1136/bmj.b2688